[{"id":"6a7737ea-7363-4409-b641-c11409e515ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181060","created_at":"2021-01-18T20:23:16.793Z","updated_at":"2025-02-25T12:37:29.255Z","phase":"Phase 3","brief_title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","source_id_and_acronym":"NCT04181060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-24"},{"id":"e7f1cf47-55e5-465b-a0d2-cff0dfd74a56","acronym":"","url":"https://clinicaltrials.gov/study/NCT03191149","created_at":"2021-01-18T15:44:05.558Z","updated_at":"2025-02-25T12:26:43.341Z","phase":"Phase 2","brief_title":"Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change","source_id_and_acronym":"NCT03191149","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 04/25/2018","start_date":" 04/25/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-24"},{"id":"13d717d6-af81-4d62-b82e-e808705b0f8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965090","created_at":"2021-07-16T13:53:19.792Z","updated_at":"2025-02-25T15:12:09.657Z","phase":"Phase 2","brief_title":"A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04965090","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-13"},{"id":"8b86d973-6a4a-4265-ab5b-f102925ec3cd","acronym":"PAPILLON","url":"https://clinicaltrials.gov/study/NCT04538664","created_at":"2021-01-18T21:43:09.446Z","updated_at":"2025-02-25T15:18:48.860Z","phase":"Phase 3","brief_title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","source_id_and_acronym":"NCT04538664 - PAPILLON","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 308","initiation":"Initiation: 10/13/2020","start_date":" 10/13/2020","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-12"},{"id":"5f3b5bbb-9aff-4571-a252-57e8a1171808","acronym":"CHRYSALIS-2","url":"https://clinicaltrials.gov/study/NCT04077463","created_at":"2021-01-18T19:58:05.927Z","updated_at":"2025-02-25T15:34:28.760Z","phase":"Phase 1","brief_title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04077463 - CHRYSALIS-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 701","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 02/03/2025","primary_completion_date":" 02/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2025-02-11"},{"id":"aef3f3cb-aa50-40d2-b1b1-727aae5c68fd","acronym":"CHRYSALIS","url":"https://clinicaltrials.gov/study/NCT02609776","created_at":"2021-01-17T17:17:24.122Z","updated_at":"2025-02-25T15:33:33.328Z","phase":"Phase 1","brief_title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02609776 - CHRYSALIS","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 751","initiation":"Initiation: 05/24/2016","start_date":" 05/24/2016","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-11"},{"id":"d34aa307-ae7e-44e1-9d9a-f7de8a535562","acronym":"PALOMA-2","url":"https://clinicaltrials.gov/study/NCT05498428","created_at":"2022-08-19T18:11:07.577Z","updated_at":"2025-02-25T15:19:56.526Z","phase":"Phase 2","brief_title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05498428 - PALOMA-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 08/05/2026","study_completion_date":" 08/05/2026","last_update_posted":"2025-02-11"},{"id":"74af1789-bdc4-49be-8227-be00ab7f39a0","acronym":"PALOMA","url":"https://clinicaltrials.gov/study/NCT04606381","created_at":"2021-01-19T20:31:31.743Z","updated_at":"2025-02-25T15:34:47.299Z","phase":"Phase 1","brief_title":"A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies","source_id_and_acronym":"NCT04606381 - PALOMA","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" MET","pipe":" | ","alterations":" EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 07/11/2024","primary_completion_date":" 07/11/2024","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2025-02-10"},{"id":"868ab017-feca-462a-908a-0cf81a5b86b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04310007","created_at":"2021-01-18T20:53:46.863Z","updated_at":"2025-02-25T16:37:47.177Z","phase":"Phase 2","brief_title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04310007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"5455e56f-c7d0-43e1-93b2-556c1632eeb2","acronym":"UCLA l-08","url":"https://clinicaltrials.gov/study/NCT04285671","created_at":"2023-11-26T01:10:15.098Z","updated_at":"2024-07-02T16:34:26.639Z","phase":"Phase 1/2","brief_title":"Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04285671 - UCLA l-08","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" HER-2 • AXL","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["HER-2 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/29/2021","start_date":" 01/29/2021","primary_txt":" Primary completion: 12/02/2025","primary_completion_date":" 12/02/2025","study_txt":" Completion: 12/02/2026","study_completion_date":" 12/02/2026","last_update_posted":"2024-06-13"},{"id":"839f620b-12d4-4a91-a1bc-669aefdc71c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496663","created_at":"2024-03-06T21:31:26.529Z","updated_at":"2024-07-02T16:34:58.872Z","phase":"Phase 1","brief_title":"Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor","source_id_and_acronym":"NCT02496663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 05/11/2016","start_date":" 05/11/2016","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"25913702-5043-4c47-af74-0e62f5ede59f","acronym":"WU-KONG15","url":"https://clinicaltrials.gov/study/NCT05559645","created_at":"2022-09-29T15:56:55.600Z","updated_at":"2024-07-02T16:35:00.588Z","phase":"","brief_title":"Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)","source_id_and_acronym":"NCT05559645 - WU-KONG15","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zegfrovy (sunvozertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-29"},{"id":"626349ae-5e92-4b7b-935d-204508ea15b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05546866","created_at":"2022-09-21T21:57:03.169Z","updated_at":"2024-07-02T16:35:00.447Z","phase":"Phase 2","brief_title":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","source_id_and_acronym":"NCT05546866","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/30/2029","primary_completion_date":" 06/30/2029","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-05-29"},{"id":"8b6df141-7b64-4f9b-89f3-9e3e39a78d70","acronym":"NCI-2017-00831","url":"https://clinicaltrials.gov/study/NCT03066206","created_at":"2021-01-17T17:10:50.278Z","updated_at":"2024-07-02T16:35:01.092Z","phase":"Phase 2","brief_title":"Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC","source_id_and_acronym":"NCT03066206 - NCI-2017-00831","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pozenveo (poziotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"e9b64c13-8122-4ab9-9ffd-428aaa84b68b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05668988","created_at":"2022-12-30T14:58:35.324Z","updated_at":"2024-07-02T16:35:01.726Z","phase":"Phase 3","brief_title":"A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)","source_id_and_acronym":"NCT05668988","lead_sponsor":"Dizal Pharmaceuticals","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Zegfrovy (sunvozertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 12/13/2022","start_date":" 12/13/2022","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-05-23"},{"id":"7fda6a16-7aec-4560-a322-7d0985c54708","acronym":"EXCLAIM-2","url":"https://clinicaltrials.gov/study/NCT04129502","created_at":"2021-01-18T20:10:25.140Z","updated_at":"2024-07-02T16:35:03.030Z","phase":"Phase 3","brief_title":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","source_id_and_acronym":"NCT04129502 - EXCLAIM-2","lead_sponsor":"Takeda","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 354","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-17"},{"id":"0f37c89c-39bf-456d-8d8e-0fef0fe7675f","acronym":"WK-KONG1","url":"https://clinicaltrials.gov/study/NCT03974022","created_at":"2021-01-18T19:32:51.357Z","updated_at":"2024-07-02T16:35:03.473Z","phase":"Phase 1/2","brief_title":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","source_id_and_acronym":"NCT03974022 - WK-KONG1","lead_sponsor":"Dizal Pharmaceuticals","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zegfrovy (sunvozertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 07/09/2019","start_date":" 07/09/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-05-15"},{"id":"1e5fae6d-b76f-41f6-b24b-b33b5b08e9ca","acronym":"ORIC-114-01","url":"https://clinicaltrials.gov/study/NCT05315700","created_at":"2022-04-07T13:56:31.880Z","updated_at":"2024-07-02T16:35:04.393Z","phase":"Phase 1/2","brief_title":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","source_id_and_acronym":"NCT05315700 - ORIC-114-01","lead_sponsor":"ORIC Pharmaceuticals","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • enozertinib (ORIC-114)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-05-10"},{"id":"4c91d9cf-6bbf-4c1f-969c-1a699ba5d11f","acronym":"FIOL","url":"https://clinicaltrials.gov/study/NCT03804580","created_at":"2021-01-18T18:48:20.019Z","updated_at":"2024-07-02T16:35:05.467Z","phase":"Phase 2","brief_title":"First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03804580 - FIOL","lead_sponsor":"Vestre Viken Hospital Trust","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-07"},{"id":"0eff7476-586f-4316-8e90-c13e90b35147","acronym":"","url":"https://clinicaltrials.gov/study/NCT06046495","created_at":"2023-09-21T15:11:06.648Z","updated_at":"2024-07-02T16:35:07.026Z","phase":"Phase 1","brief_title":"A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06046495","lead_sponsor":"Avistone Biotechnology Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e andamertinib (PLB1004)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 11/29/2023","start_date":" 11/29/2023","primary_txt":" Primary completion: 02/09/2028","primary_completion_date":" 02/09/2028","study_txt":" Completion: 02/09/2028","study_completion_date":" 02/09/2028","last_update_posted":"2024-04-30"},{"id":"d95b6e0f-bd31-40e1-a7d4-92b5c93e57e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043817","created_at":"2023-09-21T15:10:32.135Z","updated_at":"2024-07-02T16:35:08.774Z","phase":"Phase 1/2","brief_title":"First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations","source_id_and_acronym":"NCT06043817","lead_sponsor":"Scorpion Therapeutics, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STX-721"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/26/2023","start_date":" 09/26/2023","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-04-18"},{"id":"00bd8728-3f59-46ec-9a86-63c1172937ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03807778","created_at":"2021-01-18T18:49:03.389Z","updated_at":"2024-07-02T16:35:14.426Z","phase":"Phase 1","brief_title":"A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03807778","lead_sponsor":"Takeda","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR A763_Y764insFQEA • EGFR exon 20 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR A763_Y764insFQEA • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 02/04/2019","start_date":" 02/04/2019","primary_txt":" Primary completion: 11/08/2021","primary_completion_date":" 11/08/2021","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-15"},{"id":"be744523-e7d4-4a11-8136-98abcc13428e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05704634","created_at":"2023-01-30T15:59:29.317Z","updated_at":"2024-07-02T16:35:21.406Z","phase":"Phase 1","brief_title":"A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.","source_id_and_acronym":"NCT05704634","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" STK11","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR exon 18 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/18/2023","start_date":" 08/18/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-01-31"},{"id":"0fc7830f-384c-4c4c-b3b8-47d0593c8da8","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05421936","created_at":"2022-06-16T14:03:55.571Z","updated_at":"2025-02-25T15:00:28.701Z","phase":"","brief_title":"Osimertinib for NSCLC With Uncommon EGFR Mutations","source_id_and_acronym":"NCT05421936 - UNICORN","lead_sponsor":"Sheba Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Suspended","enrollment":" Enrollment 100","initiation":"Initiation: 09/27/2020","start_date":" 09/27/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-11-22"}]